None listed
Conditions
Interventions
None listed
Sponsors
National Cancer Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: - female -Over 19 years old -Histologically HER-2 positive breast cancer -Patients who are going to be administered trastuzumab after adjuvant chemotherapy with doxorubicin before surgery or adjuvant chemotherapy with doxorubicin after surgery -Patients who have written an informed consent
Exclusion criteria
Exclusion criteria: -Under 18 -Breast cancer patients expected to be treated with chemotherapy that does not contain doxorubicin or trastuzumab -Patients scheduled to use dexrazoxane -Patients diagnosed with ischemic heart disease or valve disease -Patients with atrial fibrillation or atrial fibrillation -Patients taking angiotensin converting enzyme inhibitors or angiotensin II receptor blockers or beta blockers before chemotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Early diagnosis of cardiotoxicity as an anti-cancer drug using myocardial deformation of echocardiography | — |
Secondary
| Measure | Time frame |
|---|---|
| Confirmation of the incidence of cardiotoxicity by Doxorubicin and Trastuzumab in breast cancer patients;Identification of risk factors involved in cardiotoxicity by Doxorubicin and Trastuzumab in breast cancer patients;Early diagnosis of cardiotoxicity of anticancer drugs using biochemical markers;Investigation of the correlation between the level of TOP2b expression in blood and cardiotoxicity of Doxorubicin | — |
Countries
Korea, Republic of
Contacts
Public ContactHakjin Kim
National Cancer Center
Outcome results
None listed